Liminatus

Liminatus is a clinical-stage biopharmaceutical company that develops novel cancer therapies leveraging the human immune system to recognize and attack cancer cells. The company’s development pipeline includes chimeric antigen receptor (CAR)-T cell therapy, guanylate cyclase C (GCC) cancer vaccines, and CD47 immune checkpoint inhibitors.